November 20, 2014
ASP8273, an oral compound developed by Astellas Pharma (a Japanese pharmaceutical company) is the fourth EGFR-mutant specific kinase inhibitor in development for NSCLC patients with aquired resistance to EGFR inhibition related to a T790M mutation.
Activity of this compound is promising, as ASP8273 has caused tumor shrinkage in patients in a phase I clinical trial in Japan. This response was comparable to two other drugs in development that target EGFR (Co-1689 and AZ9291), while ASP8273 has so far shown slightly reduced safety concerns. However, analysts highlight that the number of patients is still very small, and further investigations are needed to strengthen the data.
The World NSCLC Summit in Boston (January 27/28) will highlight the opportunities and challenges in the development of targeted therapies to overcome first line resistance in NSCLC.